{"id":"recombinant-human-interferon-alpha-1b","safety":{"commonSideEffects":["Flu-like symptoms","Fatigue","Fever","Headache","Myalgia","Injection site reactions"],"contraindications":["Hypersensitivity to interferon alpha or any component","Autoimmune hepatitis","Decompensated liver disease"]},"_chembl":{"chemblId":"CHEMBL1201563","moleculeType":"Protein"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Type I interferon receptor (IFNAR)","explanation":"Interferon alpha-1b binds to the type I interferon receptor complex (IFNAR1/IFNAR2) on cell membranes, activating the JAK-STAT signaling pathway. This leads to transcription of interferon-stimulated genes that enhance immune responses, inhibit viral replication, and regulate cell proliferation.","oneSentence":"Binds to interferon receptors on cell surfaces, triggering signaling cascades that induce antiviral, antiproliferative, and immunomodulatory effects."},"_scrapedAt":"2026-03-28T01:31:35.485Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122634,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"interferon alpha-2a","brand":"Roferon-A","company":"Roche","rationale":"Type I interferon with similar mechanism and therapeutic applications"},{"name":"interferon alpha-2b","brand":"Intron A","company":"Merck","rationale":"Type I interferon widely used for viral and oncologic indications"},{"name":"peginterferon alpha-2a","brand":"Pegasys","company":"Roche","rationale":"Pegylated interferon with extended half-life and improved dosing"}],"description":"Recombinant human interferon alpha-1b is a cytokine-based biologic therapy developed by Shanghai Jiao Tong University School of Medicine, currently in phase 3 clinical development. Interferons are naturally occurring proteins that modulate immune responses and have antiviral and antiproliferative properties.","indications":{"approved":[{"status":"investigational","condition":"Unknown indication","patientPopulation":"Unknown"}]},"trialDetails":[{"nctId":"NCT06212388","phase":"EARLY_PHASE1","title":"Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-01-24","conditions":"Melanoma","enrollment":10},{"nctId":"NCT05539118","phase":"PHASE1, PHASE2","title":"Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2022-09-30","conditions":"Melanoma","enrollment":48},{"nctId":"NCT04320238","phase":"PHASE3","title":"Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-01-21","conditions":"2019 Novel Coronavirus Infection","enrollment":2944}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"OFF LABEL USE"},{"count":2,"reaction":"TONSILLITIS"},{"count":1,"reaction":"COUGH"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"LUNG OPACITY"},{"count":1,"reaction":"OROPHARYNGEAL PAIN"},{"count":1,"reaction":"SARS-COV-2 ANTIBODY TEST POSITIVE"},{"count":1,"reaction":"TREATMENT FAILURE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["interferon α"],"phase":"phase_3","status":"active","brandName":"recombinant human interferon Alpha-1b","genericName":"recombinant human interferon Alpha-1b","companyName":"Shanghai Jiao Tong University School of Medicine","companyId":"shanghai-jiao-tong-university-school-of-medicine","firstApprovalDate":"","aiSummary":"Recombinant human interferon Alpha-1b is being studied in clinical trials for the treatment of melanoma and 2019 Novel Coronavirus Infection. It is being used in combination with other interventions, including ex-vivo expanded allogeneic γδ T cells and pembrolizumab, in a study to evaluate its efficacy and safety.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}